Form 4 for HCWB HCW Biologics Inc.
Accepted 2026-05-27 19:26:32 ET · period of report 2026-05-22 · accession 0001493152-26-025478 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-27 19:26 | 2026-05-22 | HCWB | Wong Hing C | CEO, Dir, 10% | P - Purchase | $1.41 | +113.9K | 615.8K | +23% | +$160.0K |
| D | 2026-05-27 19:26 | 2026-05-22 | HCWB | Wong Hing C | CEO, Dir, 10% | P - Purchase | $0.00 | +113.9K | 118.1K | +2,692% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-22 | P | A | 113,879 | $1.41 | 615,790 | D | — | — | (F1) The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. |
| 2 | Derivative | Common Stock Purchase Warrant | 2026-05-22 | P | A | 113,879 | $0.00 | 118,110 | D | $1.28 · 2026-05-22 to 2031-11-22 | 113,879 Common Stock | (F1) The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. |